Author, year | Previous NEC rate | Number of subjects | NEC in probiotic group | NEC in control group |
---|---|---|---|---|
Al-Hosni, 2012 [33] | Not stated | 50 probiotic | 3/50 any stage | 4/51 any stage |
51 control | 1/50 stage 1 | 2/51 stage 1 | ||
0/50 stage 2 | 0/51 stage 2 | |||
2/50 stage 3 | 2/51 stage 3 | |||
Bin-Nun, 2005 [40] | 15Â % | 72 probiotic | 3/72 any stage | 12/73 any stage |
73 control | 1/72 stage ≥2 | 10/73 stage ≥2 | ||
1/72 stage 2 | 7/73 stage 2 | |||
0/72 stage 3 | 3/73 stage 3 | |||
Braga, 2011 [35] | 10 % | 119 probiotic | 0/119 stage ≥2 | 4/112 stage ≥2 |
112 placebo | ||||
Costalos, 2003 [49] | Not stated | 51 probiotic | 5/51 any stage | 6/36 any stage |
36 placebo | ||||
Dani, 2002 [42] | Not stated | 295 probiotic | 4/295 stage ≥2 | 8/290 stage ≥2 |
290 placebo | ||||
Demirel, 2013 [28] | 32 % | 135 probiotic | 6/135 stage ≥2 | 7/136 stage ≥2 |
136 control | ||||
Dilli, 2015 [44] | Not stated | 100 probiotic | 2/100 stage ≥2 | 18/100 stage ≥2 |
100 placebo | ||||
Fernández-Carrocera, 2013 [32] | 20 % | 75 probiotic | 6/75 stage ≥2 | 12/75 stage ≥2 |
75 placebo | ||||
Jacobs, 2013 [26] | Not stated | 548 probiotic | 11/548 stage ≥2 | 24/551 stage ≥2 |
551 placebo | ||||
Kitajima, 1997 [52] | Not stated | 45 probiotic | 0/45 any stage | 0/46 any stage |
46 placebo | ||||
Lin, 2005 [41] | Approx. 23 % (NEC or death) | 180 probiotic | 2/180 stage ≥2 | 10/187 stage ≥2 |
187 control | 2/180 stage 2 | 4/187 stage 2 | ||
0/180 stage 3 | 6/187 stage 3 | |||
Lin, 2008 [37] | Approx. | 217 placebo | 4/217 any stage | 14/217 any stage |
217 control | 2/217 stage 2 | 9/217 stage 2 | ||
2/217 stage 3 | 5/217 stage 3 | |||
Manzoni, 2006 [37] | Not stated | 39 probiotic | 1/39 any stage | 3/41 any stage |
41 control | 1/39 stage 2 | 2/41 stage 2 | ||
0/39 stage 3 | 1/41 stage 3 | |||
Mihatsch, 2010 [43] | Not stated | 84 probiotic | 2/84 stage ≥2 | 4/82 stage ≥2 |
82 placebo | ||||
Mohan, 2006 [53] | Not stated | 21 probiotic | 2/37 stage ≥2 | 1/32 stage ≥2 |
17 placebo | Unpublished data, taken from Alfaleh 2011 [58] | Unpublished data, taken from Alfaleh 2011 [58] | ||
Oncel, 2013 [25] | 15 % | 200 probiotic | 8/200 stage ≥2 | 10/200 stage ≥2 |
200 placebo | ||||
Patole, 2014 [45] | Not stated | 74 probiotic | 0/74 stage ≥2 | 1/66 stage ≥2 |
66 placebo | ||||
Rojas, 2012 [30] | Not stated | 372 probiotic | NEC stage ≥2 | NEC stage ≥2 |
378 placebo | ≤1500 g | ≤1500 g | ||
6/176 probiotic | 10/184 placebo | |||
>1500Â g | >1500Â g | |||
3/196 probiotic | 5/194 placebo | |||
Rougé, 2009 [50] | Not stated | 45 probiotic | 2/45 any stage | 1/49 any stage |
49 placebo | ||||
Roy, 2014 [58] | Not stated | 56 probiotic | 2/56 any stage | 2/56 any stage |
56 placebo | ||||
Saengtawesin, 2014 [48] | Not stated | 31 probiotic | 1/31 stage ≥2 | 1/29 stage ≥2 |
29 placebo | ||||
Samanta, 2009 | Not stated | 91 probiotic | 5/91 stage ≥2 | 15/95 stage ≥2 |
95 control | ||||
Sari, 2011 [34] | Approx. 32 % (death or NEC) | 110 probiotic | 6/110 stage ≥2 | 10/111 stage ≥2 |
111 control | 4/110 stage 2 | 7/111 stage 2 | ||
2/110 stage 3 | 3/111 stage 3 | |||
Serce, 2013 [27] | 17 % | 104 probiotic | 7/104 stage ≥2 | 7/104 stage ≥2 |
104 placebo | ||||
Stratiki, 2007 [39] | Not stated | 41 probiotic | 0/41 stage ≥2 | 3/34 stage ≥2 |
34 control | ||||
Totsu, 2014 [46] | Not stated | 153 probiotic | 0/153 stage ≥1 | 0/130 stage ≥1 |
130 control |